Laurus Labs Ltd 2018 AR2
The report highlights Laurus Labs Limited's operational and financial performance for the fiscal year 2017-18, during which the company crossed the INR 20 billion revenue mark, representing an 8% year-on-year growth. Key achievements included expanding the formulations facility capacity at Visakhapatnam to 5 billion tablets per year and launching Tenofovir (TDF) after receiving USFDA approval. The company also expanded its global footprint by incorporating subsidiaries in the US, UK, and Germany, and commencing commercial supplies to Aspen. Additionally, Laurus Labs was certified as a 'Great Place to Work' and entered the Fortune 500 list of Indian companies.
Company: Laurus Labs Ltd
Sector: Manufacturing
Country: India
Year: 2018
Type: AR2
Pages: 212
Back to company
Laurus Labs Ltd
Annual Report
The report highlights Laurus Labs Limited's operational and financial performance for the fiscal year 2017-18, during which the company crossed the INR 20 billion revenue mark, representing an 8% year-on-year growth. Key achievements included expanding the formulations facility capacity at Visakhapatnam to 5 billion tablets per year and launching Tenofovir (TDF) after receiving USFDA approval. The company also expanded its global footprint by incorporating subsidiaries in the US, UK, and Germany, and commencing commercial supplies to Aspen. Additionally, Laurus Labs was certified as a 'Great Place to Work' and entered the Fortune 500 list of Indian companies.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Apr 1, 2017 - Mar 31, 2018
Fiscal Year
2018
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees